Talis Biomedical Corporation (TLIS)
OTCMKTS
· Delayed Price · Currency is USD
1.700
0.00 (0.00%)
Dec 27, 2024, 9:50 AM EST
Talis Biomedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 0.41 | 2.13 | 4.81 | 8.19 | 10.94 | 3.98 | Upgrade
|
| Revenue Growth (YoY) | -85.69% | -55.65% | -41.27% | -25.10% | 175.03% | 66.40% | Upgrade
|
| Cost of Revenue | 20.5 | 40.74 | 79.22 | 157.59 | 89.02 | 23.81 | Upgrade
|
| Gross Profit | -20.09 | -38.6 | -74.41 | -149.4 | -78.08 | -19.84 | Upgrade
|
| Selling, General & Admin | 26.26 | 25.45 | 37.14 | 42.42 | 13.1 | 6.86 | Upgrade
|
| Operating Expenses | 26.26 | 25.45 | 37.14 | 42.42 | 13.1 | 6.86 | Upgrade
|
| Operating Income | -46.35 | -64.05 | -111.55 | -191.82 | -91.18 | -26.7 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.1 | 4.81 | 2.13 | -0.22 | 0.05 | - | Upgrade
|
| EBT Excluding Unusual Items | -42.25 | -59.24 | -109.42 | -192.04 | -91.13 | -26.66 | Upgrade
|
| Asset Writedown | -8.77 | -2.77 | -3.59 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -0.82 | Upgrade
|
| Pretax Income | -51.03 | -62.01 | -113.01 | -192.04 | -91.13 | -27.47 | Upgrade
|
| Net Income | -51.03 | -62.01 | -113.01 | -192.04 | -91.13 | -27.47 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | -53.86 | Upgrade
|
| Net Income to Common | -51.03 | -62.01 | -113.01 | -192.04 | -91.13 | 26.38 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 0.58% | 0.95% | 19.21% | 968.49% | -1.41% | 309.45% | Upgrade
|
| EPS (Basic) | -28.02 | -34.12 | -62.77 | -127.15 | -644.69 | 515.03 | Upgrade
|
| EPS (Diluted) | -28.02 | -34.12 | -62.77 | -127.15 | -644.69 | -191.62 | Upgrade
|
| Free Cash Flow | -40.24 | -53.73 | -101.75 | -174.25 | -95.23 | -24.9 | Upgrade
|
| Free Cash Flow Per Share | -22.09 | -29.56 | -56.51 | -115.37 | -673.66 | -173.70 | Upgrade
|
| Operating Margin | -11360.29% | -3001.36% | -2318.08% | -2341.22% | -833.64% | -671.34% | Upgrade
|
| Profit Margin | -12506.37% | -2905.67% | -2348.55% | -2343.90% | -833.15% | 663.36% | Upgrade
|
| Free Cash Flow Margin | -9861.52% | -2517.62% | -2114.53% | -2126.82% | -870.59% | -626.20% | Upgrade
|
| EBITDA | -45.58 | -63.28 | -102.72 | -190.24 | -90.42 | -25.97 | Upgrade
|
| D&A For EBITDA | 0.77 | 0.77 | 8.83 | 1.58 | 0.76 | 0.73 | Upgrade
|
| EBIT | -46.35 | -64.05 | -111.55 | -191.82 | -91.18 | -26.7 | Upgrade
|
| Revenue as Reported | 0.41 | 2.13 | 4.81 | 8.19 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.